OrbiMed Advisors PEPG Position
Exited8-Fund ConvergenceOrbiMed Advisors exited their position in PepGen Inc. (PEPG) in Q1 2025, after holding the stock for 3 quarters.
The position was first reported in Q3 2024 and has been tracked across 3 quarterly 13F filings.
PEPG is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for PGN-EDODM1 in 137 days (Aug 31, 2026), making the timing of OrbiMed's position particularly relevant.
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
6.2%
5.3 days to cover
OrbiMed Advisors PEPG Position History
Frequently Asked Questions
Does OrbiMed Advisors own PEPG?
No. OrbiMed Advisors exited their position in PepGen Inc. (PEPG) in Q1 2025. They previously held the stock for 3 quarters.
How many hedge funds own PEPG?
8 specialist biotech hedge funds currently hold PEPG, including RA Capital Management, Perceptive Advisors, Commodore Capital and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy PEPG?
OrbiMed Advisors's position in PEPG was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's PEPG position increasing or decreasing?
OrbiMed Advisors completely exited their PEPG position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PEPGCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →